5 research outputs found
Nasljedni karcinom dojke i jajnika - iskustva KliniÄkog bolniÄkog centra Split
Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from October 1999 to April 2021.
Methods: The data were collected retrospectively from the medical history of 15 patients. They included the patientās age at diagnosis, family history of malignancies, histological subtype, grade, breast cancer immunophenotype, stage of disease, status and types of BRCA mutations, type of surgical and oncological treatment, the specifics of metachronous bilateral breast cancers, the specifics of synchronous breast and ovarian cancers, and the outcome of treatment through overall survival (OS).
Results: The median age of patients at the time of diagnosis of breast cancer was 53 years, and for ovarian cancer it was 56 years. A positive family history was confirmed in 13 patients (87%). All ovarian cancer patients had a high-grade serous histologic type, most often diagnosed in FIGO stages III and IV. Breast cancers were most commonly diagnosed in stages IA and IIA, with equally represented triple-negative and luminal immunophenotypes. The most common mutation was BRCA1 c.5266dup. The median OS of our patients was not reached.
Conclusion: The clinical features of patients, pathohistological characteristics of tumors, and treatment outcomes in our study population are comparable with reports in the literature, respecting the specifics of different nations and races.Cilj: Istražiti kliniÄke osobitosti, patohistoloÅ”ke karakteristike tumora, naÄin i ishode lijeÄenja bolesnica s nasljednim karcinomom dojke i jajnika koje su dijagnosticirane, lijeÄene i praÄene u KliniÄkom bolniÄkom centru Split od listopada 1999. do travnja 2021. godine.
Metode: Podatci su prikupljeni retrospektivno iz povijesti bolesti 15 bolesnica. UkljuÄivali su dob bolesnica kod dijagnoze bolesti, obiteljsku anamnezu za zloÄudne bolesti, histoloÅ”ki podtip, gradus, imunofenotip karcinoma dojke, stadij bolesti, status i tip BRCA mutacija, osobitosti kirurÅ”kog i onkoloÅ”kog lijeÄenja, specifiÄnosti metakrono nastalih bilateralnih karcinoma dojke, specifiÄnosti sinkrono nastalih karcinoma dojke i jajnika te ishod lijeÄenja kroz ukupno preživljenje.
Rezultati: Medijan dobi bolesnica u trenutku dijagnoze raka dojke bio je 53 godine, a za karcinom jajnika 56 godina. Pozitivna obiteljska anamneza potvrÄena je u 13 (87%) bolesnica. Karcinom jajnika je kod svih bolesnica bio seroznog papilarnog histoloÅ”kog podtipa visokog gradusa i najÄeÅ”Äe dijagnosticiran u FIGO stadiju III i IV. Karcinom dojke je najÄeÅ”Äe dijagnosticiran u stadiju IA i IIA, jednake zastupljenosti trostruko negativnog i luminalnog imunofenotipa. NajÄeÅ”Äa mutacija je bila BRCA1 c.5266dup. Medijan ukupnog preživljenja naÅ”ih bolesnica nije dosegnut.
ZakljuÄak: KliniÄke osobitosti bolesnica, patohistoloÅ”ke karakteristike tumora kao i ishodi lijeÄenja u naÅ”oj studijskoj populaciji su usporedivi s izvjeÅ”Äima iz literature, respektirajuÄi specifiÄnosti razliÄitih naroda i rasa
Hereditary breast and ovarian cancer : University Hospital of Split experiences
CILJ ISTRAŽIVANJA: Istražiti kliniÄke osobitosti bolesnica, karakteristike bolesti, naÄin
lijeÄenja i ishode lijeÄenja kod bolesnica s nasljednim karcinomom dojke i jajnika koje su
dijagnosticirane, lijeÄene i praÄene u Klinici za onkologiju i radioterapiju KliniÄkog bolniÄkog
centra Split u razdoblju od 01. listopada 1999. do 01. travnja 2021. godine.
ISPITANICE I METODE: Retrospektivno su prikupljeni podatci iz povijesti bolesti 15
bolesnica oboljelih od nasljednog karcinoma dojke i jajnika u razdoblju od 01. listopada 1999.
do 01. travnja 2021. godine. Prikupljeni podatci ukljuÄivali su dob bolesnice u trenutku
dijagnoze bolesti, obiteljsku anamnezu za zloÄudne bolesti, primarno sijelo bolesti, histoloÅ”ki
podtip, stupanj diferenciranosti tumora, imunofenotip karcinoma dojke, stadij bolesti, BRCA
status, vrste BRCA mutacija, osobitosti kirurÅ”kog i onkoloÅ”kog lijeÄenja, specifiÄnosti
metakrono nastalih bilateralnih karcinoma dojke, specifiÄnosti sinkrono nastalih karcinoma
dojke i jajnika te ishod lijeÄenja kroz ukupno preživljenje.
REZULTATI: Medijan dobi bolesnica u trenutku dijagnoze raka dojke iznosio je 53 godine, a
za karcinom jajnika 56 godina. Pozitivna obiteljska anamneza potvrÄena je u 13 (87%)
bolesnica. Karcinom jajnika se najÄeÅ”Äe (93%) dijagnosticirao u FIGO stadiju III i IV. Primarno
sijelo bolesti u bolesnica s rakom jajnika, jajovoda i potrbuŔnice bio je jajnik (67%), seroznog
papilarnog histoloÅ”kog podtipa gradusa 3 (100%). Karcinom dojke se najÄeÅ”Äe dijagnosticirao
u stadiju IA i IIA (67%), bio je najÄeÅ”Äe duktanog histoloÅ”kog podtipa (80%) gradusa 3 (56%),
jednake zastupljenosti trostruko negativnog i luminalnog imunofenotipa (46,7% za oba
imunofenotipa). Sve bolesnice su imale potvrÄenu BRCA mutaciju, s prevagom mutacija
BRCA1 gena (80%). NajÄeÅ”Äa BRCA mutacija u naÅ”oj studijskoj populaciji je BRCA1m
c.5266dupC i detektirana je kod 6 bolesnica. Bolesnice (87%) s karcinomom jajnika lijeÄene su
inicijalno primarnom citoredukcijom (87%) koju je slijedila kemoterapija temeljenu na platini.
Olaparib je ordiniran u 7 (46,7%) bolesnica. Sve bolesnice s karcinomom dojke lijeÄene su
inicijalno kirurÅ”kim putem, a ovisno o stadiju i imunofenotipu definirano je adjuvantno lijeÄenje
kemoterapijom (93%), radioterapijom (60%) i hormonskom terapijom (60%). Medijan
ukupnog preživljenja bolesnica s nasljednim karcinomom dojke i jajnika na naŔem uzorku nije
dosegnut. Äetiri bolesnice s metakronim bilateranim rakom dojke su imale pozitivnu obiteljsku
anamnezu na rak dojke. U svih bolesnica su najprije dijagnosticirani karcinomi dojke, a potom
karcinom jajnika. NajÄeÅ”Äa BRCA mutacija u bolesnica s bilateralnim karcinomom dojke bila
je BRCA1m c.5266dupC. Dvije bolesnice su sinkrono razvile karcinom dojke i jajnika.
Bolesnica s BRCA1 mutacijom c.843_846delCTCA uz VUS BRCA2 gena razvila je trostruko
negativni rak dojke, a druga bolesnica s BRCA2 mutacijom luminalni B HER2 negativni rak
dojke.
ZAKLJUÄAK: KliniÄke osobitosti bolesnica s nasljednim karcinom dojke i jajnika,
patohistoloÅ”ke osobitosti tumora kao i ishodi lijeÄenja u naÅ”oj studijskoj populaciji su
usporedivi s podatcima kliniÄkih studija objavljenih u dostupnoj svjetskoj medicinskoj
literaturi, respektirajuÄi specifiÄnosti razliÄitih naroda i rasa.OBJECTIVE: To investigate the clinical characteristics of patients, disease characteristics,
treatment and treatment outcomes in patients with hereditary breast and ovarian cancer who
were diagnosed, treated and monitored at the Clinic of Oncology and Radiotherapy of the
University Hospital of Split in the period from October 1, 1999 to April 1 2021.
PATIENTS AND METHODS: The data were collected retrospectively from the medical
history of 15 patients with hereditary breast and ovarian cancer in the period from October 1,
1999 to April 1, 2021. Data collected included age of patient at diagnosis, family history of
malignancies, primary disease, histological subtype, degree of tumor differentiation, breast
cancer immunophenotype, stage of disease, BRCA status, types of BRCA mutations, features
of surgical and oncological treatment, specific of metachronous bilateral breast cancers, the
specifics of synchronous breast and ovarian cancers and the outcome of treatment through
overall survival.
RESULTS: The median age of patients at the time of diagnosis of breast cancer was 53 years,
and for ovarian cancer 56 years. A positive family history was confirmed in 13 (87%) patients.
Ovarian cancer was most often (93%) diagnosed in FIGO stage III and IV. The primary site of
disease in patients with ovarian, fallopian, and peritoneal cancers was the ovary (67%), serous
papillary histological subtype grade 3 (100%). Breast cancer was most commonly diagnosed in
stage IA and IIA (67%), most often duct histological subtype (80%) grade 3 (56%), equal
representation of triple-negative and luminal immunophenotype (46.7% for both
immunophenotypes). All patients had a confirmed BRCA mutation, with a predominance of
BRCA1 gene mutations (80%). The most common BRCA mutation in our study population is
BRCA1m c.5266dupC detected in 6 patients. Patients (87%) with ovarian cancer were initially
treated with primary cytoreduction (87%) followed by platinum-based chemotherapy. Olaparib
was administered to 7 (46.7%) patients. All patients with breast cancer were initially treated
surgically, and depending on the stage and immunophenotype, adjuvant treatment with
chemotherapy (93%), radiotherapy (60%) and hormone therapy (60%) was defined. The
median overall survival of patients with hereditary breast and ovarian cancer in our sample was
not reached. Four patients with metachronic bilateral breast cancer had a positive family history
of breast cancer. All patients were diagnosed with breast cancer first and then ovarian cancer.
The most common BRCA mutation in patients with bilateral breast cancer was BRCA1m
c.5266dupC. Two patients synchronously developed breast and ovarian cancer. A patient with
the BRCA1 mutation c.843_846delCTCA in addition to the VUS BRCA2 gene developed triple-negative breast cancer, and another patient with the BRCA2 mutation developed luminal
B HER2-negative breast cancer.
CONCLUSION: The clinical features of patients with hereditary breast and ovarian cancer,
pathohistological features of tumors and treatment outcomes in our study population are
comparable with data from clinical studies published in the available world medical literature,
respecting the specifics of different nations and races
Hereditary breast and ovarian cancer : University Hospital of Split experiences
CILJ ISTRAŽIVANJA: Istražiti kliniÄke osobitosti bolesnica, karakteristike bolesti, naÄin
lijeÄenja i ishode lijeÄenja kod bolesnica s nasljednim karcinomom dojke i jajnika koje su
dijagnosticirane, lijeÄene i praÄene u Klinici za onkologiju i radioterapiju KliniÄkog bolniÄkog
centra Split u razdoblju od 01. listopada 1999. do 01. travnja 2021. godine.
ISPITANICE I METODE: Retrospektivno su prikupljeni podatci iz povijesti bolesti 15
bolesnica oboljelih od nasljednog karcinoma dojke i jajnika u razdoblju od 01. listopada 1999.
do 01. travnja 2021. godine. Prikupljeni podatci ukljuÄivali su dob bolesnice u trenutku
dijagnoze bolesti, obiteljsku anamnezu za zloÄudne bolesti, primarno sijelo bolesti, histoloÅ”ki
podtip, stupanj diferenciranosti tumora, imunofenotip karcinoma dojke, stadij bolesti, BRCA
status, vrste BRCA mutacija, osobitosti kirurÅ”kog i onkoloÅ”kog lijeÄenja, specifiÄnosti
metakrono nastalih bilateralnih karcinoma dojke, specifiÄnosti sinkrono nastalih karcinoma
dojke i jajnika te ishod lijeÄenja kroz ukupno preživljenje.
REZULTATI: Medijan dobi bolesnica u trenutku dijagnoze raka dojke iznosio je 53 godine, a
za karcinom jajnika 56 godina. Pozitivna obiteljska anamneza potvrÄena je u 13 (87%)
bolesnica. Karcinom jajnika se najÄeÅ”Äe (93%) dijagnosticirao u FIGO stadiju III i IV. Primarno
sijelo bolesti u bolesnica s rakom jajnika, jajovoda i potrbuŔnice bio je jajnik (67%), seroznog
papilarnog histoloÅ”kog podtipa gradusa 3 (100%). Karcinom dojke se najÄeÅ”Äe dijagnosticirao
u stadiju IA i IIA (67%), bio je najÄeÅ”Äe duktanog histoloÅ”kog podtipa (80%) gradusa 3 (56%),
jednake zastupljenosti trostruko negativnog i luminalnog imunofenotipa (46,7% za oba
imunofenotipa). Sve bolesnice su imale potvrÄenu BRCA mutaciju, s prevagom mutacija
BRCA1 gena (80%). NajÄeÅ”Äa BRCA mutacija u naÅ”oj studijskoj populaciji je BRCA1m
c.5266dupC i detektirana je kod 6 bolesnica. Bolesnice (87%) s karcinomom jajnika lijeÄene su
inicijalno primarnom citoredukcijom (87%) koju je slijedila kemoterapija temeljenu na platini.
Olaparib je ordiniran u 7 (46,7%) bolesnica. Sve bolesnice s karcinomom dojke lijeÄene su
inicijalno kirurÅ”kim putem, a ovisno o stadiju i imunofenotipu definirano je adjuvantno lijeÄenje
kemoterapijom (93%), radioterapijom (60%) i hormonskom terapijom (60%). Medijan
ukupnog preživljenja bolesnica s nasljednim karcinomom dojke i jajnika na naŔem uzorku nije
dosegnut. Äetiri bolesnice s metakronim bilateranim rakom dojke su imale pozitivnu obiteljsku
anamnezu na rak dojke. U svih bolesnica su najprije dijagnosticirani karcinomi dojke, a potom
karcinom jajnika. NajÄeÅ”Äa BRCA mutacija u bolesnica s bilateralnim karcinomom dojke bila
je BRCA1m c.5266dupC. Dvije bolesnice su sinkrono razvile karcinom dojke i jajnika.
Bolesnica s BRCA1 mutacijom c.843_846delCTCA uz VUS BRCA2 gena razvila je trostruko
negativni rak dojke, a druga bolesnica s BRCA2 mutacijom luminalni B HER2 negativni rak
dojke.
ZAKLJUÄAK: KliniÄke osobitosti bolesnica s nasljednim karcinom dojke i jajnika,
patohistoloÅ”ke osobitosti tumora kao i ishodi lijeÄenja u naÅ”oj studijskoj populaciji su
usporedivi s podatcima kliniÄkih studija objavljenih u dostupnoj svjetskoj medicinskoj
literaturi, respektirajuÄi specifiÄnosti razliÄitih naroda i rasa.OBJECTIVE: To investigate the clinical characteristics of patients, disease characteristics,
treatment and treatment outcomes in patients with hereditary breast and ovarian cancer who
were diagnosed, treated and monitored at the Clinic of Oncology and Radiotherapy of the
University Hospital of Split in the period from October 1, 1999 to April 1 2021.
PATIENTS AND METHODS: The data were collected retrospectively from the medical
history of 15 patients with hereditary breast and ovarian cancer in the period from October 1,
1999 to April 1, 2021. Data collected included age of patient at diagnosis, family history of
malignancies, primary disease, histological subtype, degree of tumor differentiation, breast
cancer immunophenotype, stage of disease, BRCA status, types of BRCA mutations, features
of surgical and oncological treatment, specific of metachronous bilateral breast cancers, the
specifics of synchronous breast and ovarian cancers and the outcome of treatment through
overall survival.
RESULTS: The median age of patients at the time of diagnosis of breast cancer was 53 years,
and for ovarian cancer 56 years. A positive family history was confirmed in 13 (87%) patients.
Ovarian cancer was most often (93%) diagnosed in FIGO stage III and IV. The primary site of
disease in patients with ovarian, fallopian, and peritoneal cancers was the ovary (67%), serous
papillary histological subtype grade 3 (100%). Breast cancer was most commonly diagnosed in
stage IA and IIA (67%), most often duct histological subtype (80%) grade 3 (56%), equal
representation of triple-negative and luminal immunophenotype (46.7% for both
immunophenotypes). All patients had a confirmed BRCA mutation, with a predominance of
BRCA1 gene mutations (80%). The most common BRCA mutation in our study population is
BRCA1m c.5266dupC detected in 6 patients. Patients (87%) with ovarian cancer were initially
treated with primary cytoreduction (87%) followed by platinum-based chemotherapy. Olaparib
was administered to 7 (46.7%) patients. All patients with breast cancer were initially treated
surgically, and depending on the stage and immunophenotype, adjuvant treatment with
chemotherapy (93%), radiotherapy (60%) and hormone therapy (60%) was defined. The
median overall survival of patients with hereditary breast and ovarian cancer in our sample was
not reached. Four patients with metachronic bilateral breast cancer had a positive family history
of breast cancer. All patients were diagnosed with breast cancer first and then ovarian cancer.
The most common BRCA mutation in patients with bilateral breast cancer was BRCA1m
c.5266dupC. Two patients synchronously developed breast and ovarian cancer. A patient with
the BRCA1 mutation c.843_846delCTCA in addition to the VUS BRCA2 gene developed triple-negative breast cancer, and another patient with the BRCA2 mutation developed luminal
B HER2-negative breast cancer.
CONCLUSION: The clinical features of patients with hereditary breast and ovarian cancer,
pathohistological features of tumors and treatment outcomes in our study population are
comparable with data from clinical studies published in the available world medical literature,
respecting the specifics of different nations and races
Hereditary breast and ovarian cancer : University Hospital of Split experiences
CILJ ISTRAŽIVANJA: Istražiti kliniÄke osobitosti bolesnica, karakteristike bolesti, naÄin
lijeÄenja i ishode lijeÄenja kod bolesnica s nasljednim karcinomom dojke i jajnika koje su
dijagnosticirane, lijeÄene i praÄene u Klinici za onkologiju i radioterapiju KliniÄkog bolniÄkog
centra Split u razdoblju od 01. listopada 1999. do 01. travnja 2021. godine.
ISPITANICE I METODE: Retrospektivno su prikupljeni podatci iz povijesti bolesti 15
bolesnica oboljelih od nasljednog karcinoma dojke i jajnika u razdoblju od 01. listopada 1999.
do 01. travnja 2021. godine. Prikupljeni podatci ukljuÄivali su dob bolesnice u trenutku
dijagnoze bolesti, obiteljsku anamnezu za zloÄudne bolesti, primarno sijelo bolesti, histoloÅ”ki
podtip, stupanj diferenciranosti tumora, imunofenotip karcinoma dojke, stadij bolesti, BRCA
status, vrste BRCA mutacija, osobitosti kirurÅ”kog i onkoloÅ”kog lijeÄenja, specifiÄnosti
metakrono nastalih bilateralnih karcinoma dojke, specifiÄnosti sinkrono nastalih karcinoma
dojke i jajnika te ishod lijeÄenja kroz ukupno preživljenje.
REZULTATI: Medijan dobi bolesnica u trenutku dijagnoze raka dojke iznosio je 53 godine, a
za karcinom jajnika 56 godina. Pozitivna obiteljska anamneza potvrÄena je u 13 (87%)
bolesnica. Karcinom jajnika se najÄeÅ”Äe (93%) dijagnosticirao u FIGO stadiju III i IV. Primarno
sijelo bolesti u bolesnica s rakom jajnika, jajovoda i potrbuŔnice bio je jajnik (67%), seroznog
papilarnog histoloÅ”kog podtipa gradusa 3 (100%). Karcinom dojke se najÄeÅ”Äe dijagnosticirao
u stadiju IA i IIA (67%), bio je najÄeÅ”Äe duktanog histoloÅ”kog podtipa (80%) gradusa 3 (56%),
jednake zastupljenosti trostruko negativnog i luminalnog imunofenotipa (46,7% za oba
imunofenotipa). Sve bolesnice su imale potvrÄenu BRCA mutaciju, s prevagom mutacija
BRCA1 gena (80%). NajÄeÅ”Äa BRCA mutacija u naÅ”oj studijskoj populaciji je BRCA1m
c.5266dupC i detektirana je kod 6 bolesnica. Bolesnice (87%) s karcinomom jajnika lijeÄene su
inicijalno primarnom citoredukcijom (87%) koju je slijedila kemoterapija temeljenu na platini.
Olaparib je ordiniran u 7 (46,7%) bolesnica. Sve bolesnice s karcinomom dojke lijeÄene su
inicijalno kirurÅ”kim putem, a ovisno o stadiju i imunofenotipu definirano je adjuvantno lijeÄenje
kemoterapijom (93%), radioterapijom (60%) i hormonskom terapijom (60%). Medijan
ukupnog preživljenja bolesnica s nasljednim karcinomom dojke i jajnika na naŔem uzorku nije
dosegnut. Äetiri bolesnice s metakronim bilateranim rakom dojke su imale pozitivnu obiteljsku
anamnezu na rak dojke. U svih bolesnica su najprije dijagnosticirani karcinomi dojke, a potom
karcinom jajnika. NajÄeÅ”Äa BRCA mutacija u bolesnica s bilateralnim karcinomom dojke bila
je BRCA1m c.5266dupC. Dvije bolesnice su sinkrono razvile karcinom dojke i jajnika.
Bolesnica s BRCA1 mutacijom c.843_846delCTCA uz VUS BRCA2 gena razvila je trostruko
negativni rak dojke, a druga bolesnica s BRCA2 mutacijom luminalni B HER2 negativni rak
dojke.
ZAKLJUÄAK: KliniÄke osobitosti bolesnica s nasljednim karcinom dojke i jajnika,
patohistoloÅ”ke osobitosti tumora kao i ishodi lijeÄenja u naÅ”oj studijskoj populaciji su
usporedivi s podatcima kliniÄkih studija objavljenih u dostupnoj svjetskoj medicinskoj
literaturi, respektirajuÄi specifiÄnosti razliÄitih naroda i rasa.OBJECTIVE: To investigate the clinical characteristics of patients, disease characteristics,
treatment and treatment outcomes in patients with hereditary breast and ovarian cancer who
were diagnosed, treated and monitored at the Clinic of Oncology and Radiotherapy of the
University Hospital of Split in the period from October 1, 1999 to April 1 2021.
PATIENTS AND METHODS: The data were collected retrospectively from the medical
history of 15 patients with hereditary breast and ovarian cancer in the period from October 1,
1999 to April 1, 2021. Data collected included age of patient at diagnosis, family history of
malignancies, primary disease, histological subtype, degree of tumor differentiation, breast
cancer immunophenotype, stage of disease, BRCA status, types of BRCA mutations, features
of surgical and oncological treatment, specific of metachronous bilateral breast cancers, the
specifics of synchronous breast and ovarian cancers and the outcome of treatment through
overall survival.
RESULTS: The median age of patients at the time of diagnosis of breast cancer was 53 years,
and for ovarian cancer 56 years. A positive family history was confirmed in 13 (87%) patients.
Ovarian cancer was most often (93%) diagnosed in FIGO stage III and IV. The primary site of
disease in patients with ovarian, fallopian, and peritoneal cancers was the ovary (67%), serous
papillary histological subtype grade 3 (100%). Breast cancer was most commonly diagnosed in
stage IA and IIA (67%), most often duct histological subtype (80%) grade 3 (56%), equal
representation of triple-negative and luminal immunophenotype (46.7% for both
immunophenotypes). All patients had a confirmed BRCA mutation, with a predominance of
BRCA1 gene mutations (80%). The most common BRCA mutation in our study population is
BRCA1m c.5266dupC detected in 6 patients. Patients (87%) with ovarian cancer were initially
treated with primary cytoreduction (87%) followed by platinum-based chemotherapy. Olaparib
was administered to 7 (46.7%) patients. All patients with breast cancer were initially treated
surgically, and depending on the stage and immunophenotype, adjuvant treatment with
chemotherapy (93%), radiotherapy (60%) and hormone therapy (60%) was defined. The
median overall survival of patients with hereditary breast and ovarian cancer in our sample was
not reached. Four patients with metachronic bilateral breast cancer had a positive family history
of breast cancer. All patients were diagnosed with breast cancer first and then ovarian cancer.
The most common BRCA mutation in patients with bilateral breast cancer was BRCA1m
c.5266dupC. Two patients synchronously developed breast and ovarian cancer. A patient with
the BRCA1 mutation c.843_846delCTCA in addition to the VUS BRCA2 gene developed triple-negative breast cancer, and another patient with the BRCA2 mutation developed luminal
B HER2-negative breast cancer.
CONCLUSION: The clinical features of patients with hereditary breast and ovarian cancer,
pathohistological features of tumors and treatment outcomes in our study population are
comparable with data from clinical studies published in the available world medical literature,
respecting the specifics of different nations and races
Hereditary breast and ovarian cancer ā University Hospital of Split experiences
Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from October 1999 to April 2021.
Methods: The data were collected retrospectively from the medical history of 15 patients. They included the patientās age at diagnosis, family history of malignancies, histological subtype, grade, breast cancer immunophenotype, stage of disease, status and types of BRCA mutations, type of surgical and oncological treatment, the specifics of metachronous bilateral breast cancers, the specifics of synchronous breast and ovarian cancers, and the outcome of treatment through overall survival (OS).
Results: The median age of patients at the time of diagnosis of breast cancer was 53 years, and for ovarian cancer it was 56 years. A positive family history was confirmed in 13 patients (87%). All ovarian cancer patients had a high-grade serous histologic type, most often diagnosed in FIGO stages III and IV. Breast cancers were most commonly diagnosed in stages IA and IIA, with equally represented triple-negative and luminal immunophenotypes. The most common mutation was BRCA1 c.5266dup. The median OS of our patients was not reached.
Conclusion: The clinical features of patients, pathohistological characteristics of tumors, and treatment outcomes in our study population are comparable with reports in the literature, respecting the specifics of different nations and races